Tags

Type your tag names separated by a space and hit enter

CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
J Neurol Sci. 2006 Dec 21; 251(1-2):124-8.JN

Abstract

Standard markers in cerebrospinal fluid (CSF), as soluble amyloid beta 1-42 (Abeta1-42) and total tau protein (t-tau), may contribute to dementia subtypes diagnostic accuracy. Yet, their sensitivity to assess the different degree of cognitive deficit is not fully clarified. Our study analyses Abeta1-42 and t-tau CSF levels in different cohorts of Alzheimer's disease (AD) patients, distinguished as early AD (mild cognitively impaired subjects recently converted to AD), mild AD (MMSE<23; > or =18), and moderately advanced AD (MMSE<18). The control group was represented by age-matched patients affected by depressive pseudo-dementia. Reduced Abeta1-42 and increased t-tau CSF levels were confirmed as hallmarks of AD at any disease stage. In early AD patients, Abeta1-42 levels were already significantly low, if compared to the control group (336 vs 867 ng/L; p<0.0001). On the contrary, Abeta1-42 levels did not differ between AD subgroups, and in particular between mild to moderate AD. A significant progressive increase of t-tau concentration was found when comparing early AD (269 ng/L) to more advanced AD stages (468 ng/L and 495 ng/L for mild and moderate AD, respectively). Our findings confirm that the impairment of amyloidogenic cascade is an early, even pre-clinical process, but suggest that soluble Abeta1-42 concentration has a negligible correlation with the clinical progression. Conversely, t-tau concentration correlates with the transition towards marked cognitive impairment.

Authors+Show Affiliations

IRCCS-Fondazione S Lucia, Rome, Italy. stefani@uniroma2.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17097109

Citation

Stefani, Alessandro, et al. "CSF Markers in Alzheimer Disease Patients Are Not Related to the Different Degree of Cognitive Impairment." Journal of the Neurological Sciences, vol. 251, no. 1-2, 2006, pp. 124-8.
Stefani A, Martorana A, Bernardini S, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci. 2006;251(1-2):124-8.
Stefani, A., Martorana, A., Bernardini, S., Panella, M., Mercati, F., Orlacchio, A., & Pierantozzi, M. (2006). CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the Neurological Sciences, 251(1-2), 124-8.
Stefani A, et al. CSF Markers in Alzheimer Disease Patients Are Not Related to the Different Degree of Cognitive Impairment. J Neurol Sci. 2006 Dec 21;251(1-2):124-8. PubMed PMID: 17097109.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. AU - Stefani,Alessandro, AU - Martorana,Alessandro, AU - Bernardini,Sergio, AU - Panella,Marta, AU - Mercati,Flavio, AU - Orlacchio,Antonio, AU - Pierantozzi,Mariangela, Y1 - 2006/11/09/ PY - 2006/05/02/received PY - 2006/09/18/revised PY - 2006/09/19/accepted PY - 2006/11/14/pubmed PY - 2007/2/23/medline PY - 2006/11/14/entrez SP - 124 EP - 8 JF - Journal of the neurological sciences JO - J Neurol Sci VL - 251 IS - 1-2 N2 - Standard markers in cerebrospinal fluid (CSF), as soluble amyloid beta 1-42 (Abeta1-42) and total tau protein (t-tau), may contribute to dementia subtypes diagnostic accuracy. Yet, their sensitivity to assess the different degree of cognitive deficit is not fully clarified. Our study analyses Abeta1-42 and t-tau CSF levels in different cohorts of Alzheimer's disease (AD) patients, distinguished as early AD (mild cognitively impaired subjects recently converted to AD), mild AD (MMSE<23; > or =18), and moderately advanced AD (MMSE<18). The control group was represented by age-matched patients affected by depressive pseudo-dementia. Reduced Abeta1-42 and increased t-tau CSF levels were confirmed as hallmarks of AD at any disease stage. In early AD patients, Abeta1-42 levels were already significantly low, if compared to the control group (336 vs 867 ng/L; p<0.0001). On the contrary, Abeta1-42 levels did not differ between AD subgroups, and in particular between mild to moderate AD. A significant progressive increase of t-tau concentration was found when comparing early AD (269 ng/L) to more advanced AD stages (468 ng/L and 495 ng/L for mild and moderate AD, respectively). Our findings confirm that the impairment of amyloidogenic cascade is an early, even pre-clinical process, but suggest that soluble Abeta1-42 concentration has a negligible correlation with the clinical progression. Conversely, t-tau concentration correlates with the transition towards marked cognitive impairment. SN - 0022-510X UR - https://www.unboundmedicine.com/medline/citation/17097109/CSF_markers_in_Alzheimer_disease_patients_are_not_related_to_the_different_degree_of_cognitive_impairment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(06)00425-4 DB - PRIME DP - Unbound Medicine ER -